co
challeng cloud outlook
sometim tempt recommend buy stock significantli pull
back seem market reaction news may seem punit
short-sight manag guidanc incorpor impact event
seem conserv emb perhap worst case scenario sinc
announc result reduct guidanc due infus
pump updat share vs flat surfac becton
dickinson seem fit situat view best stay sidelin
maintain equal weight rate share reduc pt
pump situat colleagu still earli lot visibl
bd announc alari pump softwar remedi plan requir file
current anticip submit turn result
ship hold clearanc result bd reduc guidanc sale
ep repres replac pump sale vs share
gain expect recaptur post baxter could
benefit new pump expect launch juli also consid
integr pump hospit consider believ share
loss would limit see baxter colleagu pump situat
decad ago allow carefusion/bd gain substanti share discuss herein
outlook reduc bigger pictur bd growth outlook unchang view
reduc near-term financi outlook henc pt ep
prior see long-term growth larg unchang
alari pump issu resolv still see bd top-lin ep
grower anyth push-out/recaptur help outlook bd
reach leverag target ye bd expect avail valu
creation opportun start plan focu tuck-in dont see
anoth transform deal also note bd product liabil claim
expect return share repurchas increas annual dividend
said multipl seem fair us given uncertainti risk henc equal weight
quarterli annual ep usd
consensu number bloomberg receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
idc link barclay live interact chart
barclay co
co
equal weight believ alari pump
issu like remain overhang stock
greater clariti also believ stock
fairli valu given risk lack clariti
around pump issu
upsid case ep could driven
synergi associ bard acquisit
improv overal growth rate btk
indic earlier resolut alari pump
downsid case ep could driven
foreign exchang stronger usd could
slowdown emerg market growth/china fda
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
barclay co
result solid sale fx neutral come ahead
street/our estim well guidanc ep beat street
expect high-end guidanc despit upsid bd lower
sale ep guidanc reflect alari pump
remedi effort manag guidanc could prove conserv
remov virtual alari pump sale stock pull back
maintain equal weight remain uncertainti around fda clearanc time
addit detail quarter
million except per share data chang sale constant currenc basi unless otherwis note
sale fx neutral basi manag guidanc
ep high end guidanc strength
underli busi help off-set expect alari china tender headwind
peripher intervent manag note dcb sale come
better expect new product drive growth
bd life scienc sale strength bioscienc driven
licens revenu demand instrument reagent diagnost
system also saw broad-bas strength
compani continu work fda softwar remedi plan
alari pump system understand need submit file
softwar updat plan receiv
fda clearanc unabl ship pump may continu
consequ bd lower sale ep guidanc reflect impact
alari pump remedi effort impact respect
coronaviru expect net headwind
medic deliveri sale rel flat owe expect weak
china cathet busi result volume-bas procur initi
expect impact prior estimate howev
manag expect strength rest china busi strength
area across bd off-set weak
sale fx neutral basi growth driven life
scienc intervent off-set medic
gross margin y/i reflect continu improv
initi cost synergi partial off-set price
sg sale y/i reflect addit defer
compens expens due strong stock perform underli basi
sg grew line sale
 sale y/i
oper margin y/i driven higher sg
adjust tax rate y/i due tough comparison result
discret item
adjust ep y/i fx neutral basi
bd expect fx neutral growth includ expect headwind coronaviru bd expect adjust ep
bd lower fx neutral sale growth expect prior reflect alari pump issu fx
expect headwind bring report sale growth guidanc divis bd expect medic flat prior
life scienc intervent expect high end rang respect adjust ep
guidanc lower prior reflect fx neutral growth prior
estimate sale mrptdc-fxnbd management compar fx neutral basisyoy changebd barclay co
infus pump manag administr fluid medic and/or nutrient
patient constant control rate
larg volum infus pump gener cost around although price
vari design softwar featur pump purchas outright leas
pump multi-channel mean deliv fluid multipl reservoir
multipl rate newer advanc smart-pump offer addit featur
medic safeti manag patient perform track pump specif profil
wireless integr hospit typic purchas one pump everi bed facil
normal buy pump time bed thu individu basi pump
signific expenditur aggreg costli consid size
hospit may sever hundr hospit bed moreov given integr
complex purchas pump usual replac seven year although pump
oper year maintain properli
patient control analgesia pca pump specialti pump allow patient
control administr intraven analges drug often set limit
amount medic dose particular time period
syring pump fluid contain within reservoir syring
estim market infus pump relat dispos set approxim
billion valu grow low single-digit unit state
market share leader acquisit carefus legaci alari busi
would estim approxim two-third market today gain
time larg baxter baxter-equ weight market share leader
baxter lost leadership posit owe persist recal colleagu pump
culmin consent decre wherebi offer custom option provid
either new sigma spectrum pump cash option purchas competitor pump
believ distinct import realiz review histori colleagu later
report manufactur includ icu medic icui-not cover braun
baxter alon qualiti issuesal major pump player includ
carefus alari pump share pump qualiti issu
problem includ softwar problem alarm issu poor user design human
factor batteri failur sparks/shocks/shortag broken compon
fda launch infus improv initi includ three action
establish addit requir infus pump manufactur proactiv
facilit devic improv increas user awar initi result
final guidanc document
bd sent recal letter custom februari notifi custom
issu softwar error relat system error code
issu keep vein open kvo end infus alarm prioriti
barclay co
issu use error relat custom concentr program
bd commun custom work fda resolv
issu commun timelin resolut regard softwar fix
manag comment earn call last week plan file
fda summer/dur review could take day
dont see alari baxter colleagu recal
baxter colleagu infus pump clear fda decemb
soon follow clearanc troubl began baxter start document
occurr batteri temperatur specif lead pump failur
septemb august baxter receiv fda warn letter relat failur
conform fda qualiti system regul
march baxter initi recal colleagu infus pump notifi user
design issu wherebi someon could inadvert press on/off key instead
start key baxter also notifi custom extern commun port failur
user fail power pump connect disconnect cabl juli
fda classifi recal class recal octob fda seiz
colleagu syndeo pca syring pump ensur pump distribut
problem correct pump use loaner
june baxter enter consent decre fda outlin step
necessari return product market resolv court action began
seizur pump decemb baxter receiv condit approv
colleagu correct action plan submit updat pre-market approv
notif subsequ clear fda februari june
baxter start contact account recent upgrad alarm
notif error code stop infus juli fda fda
classifi baxter correct action recent manufactur upgrad colleagu
tripl channel infus pump total class recal moreov baxter
discov colleagu flogard pump brought mainten
falsifi servic repair data need recal
octob baxter announc identifi fix tripl channel pump
final stage test valid softwar modif januari
baxter comment expect re-commerci april
becam clear resolut timelin possibl januari baxter
comment remedi single-channel pump remain
activ dialogu fda relat addit softwar modif clinic
evalu pump enhanc investor day septemb baxter
manag comment hope complet follow-on remedi effort
howev time colleagu pump year old
design smart-pump go replac acquir spectrum
april baxter submit propos correct schedul fda state
baxter plan begin latest round colleagu correct may
complet expect howev may fda announc
baxter plan unaccept order baxter recal destroy
colleagu infus pump us provid either replac infus pump
sigma pump refund owner transit period
barclay co
baxter requir notifi custom provid transit guid within two
month sign final order fda continu use colleagu
transit period facil need fill form certifi medic necess
specifi date expect remov colleagu facil transit guid
contain inform suitabl fda approv clear altern respect
manufactur way minim disrupt reduc risk patient way train staff
list consult assist facil verif valid
altern pump refund amount base depreci valu pump
owner document purchas price whichev less minimum depreci
pump valu singl channel colleagu pump tripl channel
believ fact baxter mandat provid option custom
cash option educ custom option market import differ
rel current situat alari moreov baxter come new
pump juli thu believ custom like want wait see pump
assess option
guidanceguid updatenovemberfebruaryrevenu growth metricsreport fxn growthbd life high end bd high end total metricsgross tax metricsoper barclay co
link note click titl link barclay live
also first look guidanc reduc never mind flu/virus today go
alari
model avail barclay live upon request
model avail barclay live
link click
barclay co
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
